Tech Company Financing Transactions
Kaleido Biosciences Funding Round
Flagship Pioneering invested in a $65 million venture round for Kaleido Biosciences. The round was announced on 9/19/2017.
Transaction Overview
Company Name
Announced On
9/19/2017
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Undisclosed
Investors
Flagship Pioneering (Noubar Afeyan)
Proceeds Purpose
Guided by a mission to fundamentally change the metabolic profile of the human microbiome to improve serious health conditions and diseases, we anticipate an exciting year of growth and expansion ahead.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Hayden Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Kaleido is dedicated to leading a revolution in health. It all starts with the microbiome. In the last ten years, science has revealed the microbiome to be one of the most diverse, powerful organs in the body. At Kaleido, we are pioneering new ways to unlock its power to enable the body to treat disease and heal itself.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Bonney
Chief Executive Officer
Alison Lawton
Chief Financial Officer
William Duke
Chief Medical Officer
Katharine Knobil
Chief Scientific Officer
Johan van Hylckama Vlieg
Co-Founder
Geoffrey von Maltzahn
VP - Bus. Development
Clare Fisher
VP - General Counsel
Jerald Korn
Browse more venture capital transactions:
Prev: 9/19/2017: FreeWire Technologies venture capital transaction
Next: 9/19/2017: Cofactor Genomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs